Full Professor
Strategic program(s):
Biography
Onno Kranenburg received his PhD in 1995 from Leiden University under supervision of Prof Alex van der Eb. After a post-doc in the Netherlands Cancer Institute, he moved to UMC Utrecht where he started his translational studies on the mechanism of action of anti-angiogenic drugs in the group of Prof Emile Voest. In 2003 he became Assistant Professor and PI at the Department of Surgery with Prof Inne Borel Rinkes and started to work on the mechanisms of colon cancer metastasis. In 2006 he became Associate Professor, head of the Surgery Lab and staff member at the Department of Surgery. In 2012 he became coordinator of the PhD research school Clinical and Translational Oncology, which he currently heads as director. In 2015 he was appointed Professor of Surgical and Translational Tumor Biology and founded the Lab Translational Oncology, where he continues to design and test novel strategies for the prevention and treatment of colon cancer metastasis. He also founded and chairs the Utrecht Platform for Organoid Technology, now a central facility in the UMCU that stimulates organoid-based biomedical and clinical research.
Research aim
To develop, test, and implement novel therapeutic and diagnostic strategies to combat cancer by integrating fundamental and clinical research.
Go to group1. KWF2015-8088. Targeting mesenchymal-tyope colon cancer by aggravating oxidative damage. €573.500.
2. Scope: Modulation of chemotherapy efficacy and toxicity by nutrition in metastatic colorectal cancer. €586.000.
3. ZonMw 2014: PDGF-receptor-targeted therapy for the treatment of poor prognosis mesenchymal-type colon cancer: A window trial. €108.000
4. Gieskes-Strijbis Fonds 2014: The relationship between primary colorectal tumors and their liver metastases: Biological subgroups and therapy response. €290.000
5. Vrienden UMC Utrecht 2013. Title: Targeting colon tumors at their root: Elimination of Cancer Stem Cells. €217.000
6. KWF UU2011-5226 Title: LIMK1 control of CD95 function in colorectal cancer. €553.300
7. KWF UU2011-5135. Suppression of LIMK1 by oncogenic KRAS and RAF1: A critical survival pathway in colorectal cancer? €560.000
8. KWF UU2009-4417. The contribution of CD95 signalling to recurrence of colorectal liver metastases following radiofrequency ablation. €592.100
Chair - supervision UPORT facility team - Utrecht Platform for Organoid technology